Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature

By sjmartinez • January 2, 2025

Barghi A, Noveir SD, Mainwaring W, Milani-Nejad N, Bernet L. Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature. Int J Dermatol. 2024 Dec 30. doi: 10.1111/ijd.17626. Epub ahead of print. PMID: 39739856.

Tags: bullous pemphigoid, Dermatology, DGSOM Student, Dupilumab, eosinophilic annular erythema, immune checkpoint inhibitor, pembrolizumab, Publications

Do female patients see their physicians differently? A population-based study evaluating perception of physician communication by patients with hidradenitis suppurativa

Harvey LF, Kingston P, Kikuchi R, Manasyan A, Sadrolashrafi K, Hao A, Tolson H, Yee D, Armstrong AW. Do female patients see their physicians differently?[...]

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation

Armstrong AW, Gondo GC, Merola JF, Roberts AM, Pérez-Chada LM, Balak DMW, Eakin GS, Read C, Le ST, Gutierrez Y, Bhutani T, Blauvelt A, Duffin[...]

Scarring alopecia as an unexpected consequence of immune checkpoint inhibition

Kokikian N, Tarabay J, Goh C. Scarring alopecia as an unexpected consequence of immune checkpoint inhibition. JAAD Case Rep. 2025 May 8;61:1-6. doi: 10.1016/j.jdcr.2025.04.007. PMID:[...]